Allakos Inc. is a privately held, product-focused biotechnology company developing first-in-class antibody-based therapeutics to treat diseases in which dysregulation of the T-helper type 2 (Th2) immune response plays a key role in pathology, including allergic disease, inflammation and diseases characterized by excess production of inflammatory cells. Allakos has generated a preclinical pipeline of novel antibodies targeting cell types implicated in allergic and inflammatory responses, which it intends to advance to clinical proof-of-concept.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 12/17/12 | $32,000,000 | Series A |
Alta Partners Novo Ventures RiverVest Venture Partners Roche Venture Fund | undisclosed |
| 09/30/14 | $10,000,000 | Series A Extension |
Alta Partners Novo Novo Ventures RiverVest Venture Partners Roche Venture Fund | undisclosed |
